Public Release: 

Hepatitis A hospitalization rate declines in US


New research reports that the rate of hospitalization due to hepatitis A virus (HAV) infection has significantly declined in the U.S. from 2002 to 2011. Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that older patients and those with chronic liver disease are most likely to be hospitalized for HAV. Vaccination of adults with chronic liver disease may prevent infection with hepatitis A and the need for hospitalization.

The World Health Organization (WHO) estimates that each year 1.4 million individuals worldwide are infected with HAV--a viral liver disease that is transmitted by ingesting contaminated food or water, or direct contact with someone infected with the virus. While cases of HAV infection have decreased by 90% in the U.S. over the past two decades, there are still about 2,000 new cases each year according to the Centers for Disease Control and Prevention (CDC).

The study led by Dr. Melissa Collier from the Division of Viral Hepatitis at the CDC in Atlanta, Georgia the present study examines trends in HAV-related hospitalizations in the U.S. Using the National Inpatient Survey discharge data, researchers identified patients hospitalized for primary hepatitis A in the U.S. between 2002 and 2011.

Results show that the rate of hospitalization for HAV infection as a principal diagnosis decreased from 0.72 to 0.29 per 100,000 cases during the study period. During the same time period the average age of hospitalized patients increased from 38 to 46 years, with the percentage of HAV-related hospitalizations covered by Medicare also increasing from 12% to 23%.

Additional analysis found an increase in accompanying diseases (comorbidities) that include liver disease, hypertension, heart disease, metabolic syndromes, and chronic kidney disease. The research team did not report any changes in the length of hospitalization or in-hospital deaths due to hepatitis A , though patients with liver disease required longer hospital stays.

This study found hospitalizations due to illness from hepatitis A have declined. However, this disease seems to be more troublesome for older patients and those with liver disease or other chronic conditions. The authors note that adult vaccination may help prevent hepatitis A and suggest that clinicians consider vaccinating patients in high risk groups.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.


This study is published in Hepatology. Media wishing to receive a PDF of this article may contact

Full citation: "Hepatitis A Hospitalizations in the United States, 2002 - 2011." Melissa G. Collier, Xin Tong and Fujie Xu. Hepatology; (DOI: 10.1002/hep.27537)


Author Contact: Media wishing to speak with Dr. Collier may contact the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention at +1 404-639-8895 or at

Media Advisory

The Liver Meeting® 2014

Founded in 1950, AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD has grown into an international society responsible for all aspects of hepatology, and the annual meeting attracts 10,000 physicians, surgeons, researchers, and allied health professionals from around the world. The Liver Meeting® is the premier meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies. When: November 7 - 11, 2014

Where: Hynes Convention Center in Boston, Massachusetts

Contact: Please go to to obtain a press pass for this event.

About the Journal

Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit

About Wiley

Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.

Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's website can be accessed at

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.